CrushSCI.com
141.1Average days
125Median days
53Fastest days
274Longest days
3502025 publications

Paper Review Records

All Paper Review Records

19 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

169 days

Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR -altered non-small-cell lung cancer

Authors
Natasha B. Leighl; Antonio Passaro; Hiroaki Akamatsu; Alexander I. Spira; Danny Nguyen; Angel Qin; Julia Schuchard; Mohamed Gamil; Mahadi Baig; Mariam AlexanderShow moreShow less
Affiliations
1. aPrincess Margaret Cancer Centre, Toronto, ON, Canada; 2. bDivision of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy; 3. cInternal Medicine III, Wakayama Medical University, Wakayama, Japan; 4. dVirginia Cancer Specialists, Fairfax, VA, USA; 5. eCity of Hope National Medical Center, Duarte, CA, USA; 6. fUniversity of Michigan Rogel Cancer Center, Ann Arbor, MI, USA; 7. gJohnson & Johnson, Horsham, PA, USA; 8. hJohnson & Johnson, Spring House, PA, USA; 9. iJohnson & Johnson, Raritan, NJ, USA; 10. jHollings Cancer Center, Medical University of South Carolina, Charleston, SC, USAShow moreShow less
Source PDF DOI Publisher page
62 days

Cancer control after pausing treatment with larotrectinib in responding children with sarcoma and a TRK fusion: a plain language summary

Authors
Leo Mascarenhas; Christopher Ollis; Yuvraj Singh; Linet Menachery; Domnita-Ileana Burcoveanu; Esther De La Cuesta; Cornelis M van Tilburg; Theodore W LaetschShow moreShow less
Affiliations
1. aGuerin Children’s and Cedars-Sinai Cancer, Cedars-Sinai Health Sciences University, Los Angeles, CA, USA; 2. bPatient author; 3. cValley Springs, CA, USA; 4. dCaregiver author, Gurugram, Haryana, India; 5. eCaregiver author, White Plains, NY, USA; 6. fBayer HealthCare Pharmaceuticals, Inc, Basel, Switzerland; 7. gBayer HealthCare Pharmaceuticals, Inc, Whippany, NJ, USA; 8. hHopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany; 9. iClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany; 10. jHeidelberg University, Heidelberg Faculty of Medicine, Department of Pediatric Oncology, Hematology, Immunology, and Pulmonology, Heidelberg University Hospital, Heidelberg, Germany; 11. kNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany; 12. lChildren’s Hospital of Philadelphia / University of Pennsylvania, Philadelphia, PA, USAShow moreShow less
Source PDF DOI Publisher page
163 days

Prognostic disparities between radioactive iodine-refractory and non-refractory DTC patients: a cohort study on survival rates and independent risk factors

Authors
Menghua Xia; Weifu Lv; Wei Zhao; Liqin Bi; Xueran Guo; Mengxia Zhang; Liangping ShiShow moreShow less
Affiliations
1. The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of Life Sciences and Medicine, University of Science and Technology of ChinaShow moreShow less
Source PDF DOI Publisher page
183 days

Smoldering multiple myeloma: a multi-country mixed-methods study on disease perceptions and patient treatment preferences

Authors
Matthew Quaife; Cecilia Jimenez-Moreno; Blanca Gros Otero; Aisha Asra; Niodita Gupta-Werner; Katharine S. Gries; Marie-Kristin Leisten; Kathryn Matt; Robin Carson; Robyn Dennis; Jianming He; Bennett Levitan; Sacheeta BathijaShow moreShow less
Affiliations
1. Evidera; 2. Johnson & JohnsonShow moreShow less
Source PDF DOI Publisher page
196 days

Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study

Authors
Shan Xu; Hao Yang; Nan HuShow moreShow less
Affiliations
1. The Third Affiliated Hospital of Nanjing Medical University; 2. The Third Affiliated Hospital of Soochow UniversityShow moreShow less
Source PDF DOI Publisher page
239 days

A pragmatic adaptation of the RANO clinical risk score for IDH-Wildtype glioblastoma in the absence of MGMT promoter methylation testing

Authors
İmdat Eroğlu; Sıla Soylu Koçoğlu; Eron Merovci; Gözde Savaş; Fatih Gürler; Osman Sutcuoglu; Ugur Coskun; Aytug Uner; Murat Ucar; Burak Karaarslan; Ahmet Özet; Nuriye Özdemir; Ozan YazıcıShow moreShow less
Affiliations
1. Gazi University School of MedicineShow moreShow less
Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.